Diaceutics PLC
DXRX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 35.7% | 21.5% | 39.9% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 87.9% | 83.2% | 72% | 75.8% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £0 | £0 | £0 | £0 |
| Sales & Mktg Exp. | £0 | £0 | -£0 | -£0 |
| Other Operating Expenses | -£0 | -£0 | £0 | £0 |
| Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Income | -£0 | -£0 | £0 | £0 |
| % Margin | -7.6% | -12.7% | 2.9% | 3.9% |
| Other Income/Exp. Net | £0 | £0 | -£0 | -£0 |
| Pre-Tax Income | -£0 | -£0 | £0 | £0 |
| Tax Expense | -£0 | -£0 | -£0 | -£0 |
| Net Income | -£0 | -£0 | £0 | £0 |
| % Margin | -5.3% | -7.4% | 3.7% | 4% |
| EPS | -0.02 | -0.021 | 0.009 | 0.007 |
| % Growth | 2.4% | -340.7% | 28.4% | – |
| EPS Diluted | -0.02 | -0.021 | 0.008 | 0.007 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | £0 | £0 | £0 | £0 |
| % Margin | 8.6% | 10% | 18.5% | 16.8% |